This is a preview of subscription content, log in via an institution to check access.
References
Bottomley SS, Fleming MD (2014) Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am 28:653–670. doi:10.1016/j.hoc.2014.04.008
Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Ishiyama K, Mori H, Nolte F, Hofmann WK, Miyawaki S, Sugano S, Haferlach C, Koeffler HP, Shih LY, Haferlach T, Chiba S, Nakauchi H, Miyano S, Ogawa S (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69. doi:10.1038/nature10496
Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y, Manabe A, ItoE OK, Kojima S, Ogawa S, Harigae H (2013) Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol 92:1–9. doi:10.1007/s00277-012-1564-5
Cotter PD, May A, Fitzsimons EJ, Houston T, Woodcock BE, al-Sabah AI, Wong L, Bishop DF (1995) Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 96:2090–2096
Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF (2000) Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood 96:4363–4365
Cazzola M, Malcovati L (2015) Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. Hematology Am Soc Hematol Educ Program 2015:19–25. doi:10.1182/asheducation-2015.1.19
Kadirvel S, Furuyama K, Harigae H, Kaneko K, Tamai Y, Ishida Y, Shibahara S (2012) The carboxyl-terminal region of erythroid-specific 5-aminolevulinate synthase acts as an intrinsic modifier for its catalytic activity and protein stability. Exp Hematol 40:477–486. doi:10.1016/j.exphem.2012.01.013
Katsurada T, Kawabata H, Kawabata D, Kawahara M, Nakabo Y, Takaori-Kondo A, Yoshida Y (2016) A Japanese family with X-linked sideroblastic anemia affecting females and manifesting as macrocytic anemia. Int J Hematol 103:713–717. doi:10.1007/s12185-016-1949-7
Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP (2015) X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest 125:1665–1669. doi:10.1172/JCI78619
Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R, Noji H, Yokoyama H, Tomiya Y, Kato Y, Ishizawa K, Ito S, Ishida Y, Sawada K, Harigae H (2016) Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114and 130 f. as critical markers for categorization. Int J Hematol 104:344–357. doi:10.1007/s12185-016-2043-x
Acknowledgements
We thank the staff of the Department of Hematology and Rheumatology for helpful discussions. We appreciate Dr. Mitsue Inomata (Hematology, Sendai National Center) for providing clinical information.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
After obtaining written informed consent, we conducted Sanger sequencing to identify the genetic alteration associated with RS formation
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Fujiwara, T., Fukuhara, N., Ichikawa, S. et al. A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review. Ann Hematol 96, 1955–1957 (2017). https://doi.org/10.1007/s00277-017-3106-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-017-3106-7